engleski

Cell type-dependent response to chemotherapy treatment with doxorubicin in breast cancer

Breast cancer still represents leading cause of mortality and morbidity in women nevertheless of the great improvements in early diagnostics and cancer therapy made in the last few decades. Even though these improvements led to better understanding of the underlying molecular mechanisms, resistance to classical chemotherapeutics is still a tremendous challenge for breast cancer therapy. About 30% of all breast cancer patients who are successfully treated at early stages are suffering a relapse accompanied by metastasis and chemoresistance to classical drugs. Among the wide variety of drugs used in breast cancer chemotherapy treatments, doxorubicin is frequently used either as single-agent or in combination with other drugs. Since breast cancer is heterogeneous disease it can be categorised into three basic therapeutic groups: hormone (oestrogen (ER) and progesterone (PR)) positive with the best prognosis, HER2 positive and triple-negative(ER-, PR-, HER2-) with the worst prognosis. These subtypes were shown to respond differently to chemotherapy. On the other hand we must not neglect the role of the microenvironment, especially extracellular matrix (ECM) and its modifications, on the cancer treatment and its prevention or progression. Therefore we have investigated the effect of doxorubicin treatment and 4-hydroxynonenal-modified microenvironment, in the 3 different breast cancer cell lines: MCF-7 (ER+, Pr+), SkBr3 (Her2+) and SUM 159 (triple negative). Our results of cell proliferation and Intracellular reactive oxygen species (ROS) production have revealed difference in cell type responses.

breast cancer; chemotherapy; doxorubicin

nije evidentirano